enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Roche settles US patent lawsuit against Biogen over ...

    www.aol.com/news/roche-settles-us-patent-lawsuit...

    Roche and its subsidiaries Genentech and Chugai Pharmaceutical jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera had agreed to settle the case.

  3. Genentech - Wikipedia

    en.wikipedia.org/wiki/Genentech

    Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]

  4. Sangamo Therapeutics Stock Plunges As Pfizer Terminates ...

    www.aol.com/sangamo-therapeutics-stock-plunges...

    Sangamo believes that its recently announced partnerships with Roche Holdings AG’s (OTC:RHHBY) Genentech and Astellas Pharma Inc (OTC:ALPMF) (OTC:ALPMY) and advanced business development ...

  5. Genentech withdraws use of Gavreto in US for a type of ... - AOL

    www.aol.com/news/genentech-withdraws-gavreto-us...

    Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...

  6. Bill Anderson (businessman) - Wikipedia

    en.wikipedia.org/wiki/Bill_Anderson_(businessman)

    From 2017 to 2018, he was the CEO of Genentech. [6] While at Genentech, he developed its immunology and ophthalmology divisions, managed the sales of Rituxan, Raptiva, and Xolair, and directed Roche's late-stage portfolio committee for nearly four years, where he was responsible for determining late-stage clinical trial advancements. [6]

  7. Polatuzumab vedotin - Wikipedia

    en.wikipedia.org/wiki/Polatuzumab_vedotin

    The FDA granted the approval of Polivy to Genentech. [9] Polatuzumab vedotin was approved for medical use in the European Union in January 2020, as a second-line treatment. [7] The European Medicines Agency (EMA) designated polatuzumab vedotin an orphan medicine in April 2018. [7]

  8. Roche: have abandoned some trials due to U.S. drug ... - AOL

    www.aol.com/news/roche-abandoned-trials-due-u...

    FRANKFURT (Reuters) -Roche said it had abandoned certain drug development projects or acquisitions under consideration because of planned price cuts in best-selling prescription medicines in the ...

  9. Aviv Regev - Wikipedia

    en.wikipedia.org/wiki/Aviv_Regev

    Aviv Regev (born 11 July 1971) [3] is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. [4] She is a core member (on leave) at the Broad Institute of MIT and Harvard and professor (on leave) at the Department of Biology of the Massachusetts ...